Radiation Therapy Compared With No Further Treatment Following Surgery in Treating Patients With Prostate Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentCompleted75 and underOtherEORTC-22911
EORTC-GU-22911, NCT00002511

Trial Description


RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for prostate cancer.

PURPOSE: Randomized phase III trial to compare radiation therapy with no further treatment in treating patients with stage III prostate cancer following radical prostatectomy.

Further Study Information


  • Compare local recurrence rates, acute and late morbidity, overall survival, disease-free survival, and cancer-related survival of patients with pT3 pN0 adenocarcinoma of the prostate randomized following radical prostatectomy to postoperative conventional pelvic irradiation (60 Gy) vs no further treatment until relapse.
  • Better define the selective pathologic indications for radiotherapy in patients with pT3 pN0 disease.

OUTLINE: This is a randomized study.

  • Arm I: Patients undergo radiotherapy daily, 5 days a week, for 5 weeks, followed by boost radiotherapy for 1-1.4 weeks.
  • Arm II: Patients are observed. Local relapse is treated with conventional pelvic radiotherapy.

Patients are followed every 3 months during the first postoperative year, every 6 months until the fifth year, and annually thereafter.

PROJECTED ACCRUAL: A total of 1000 patients will be accrued for this study within 7.5 years.

Eligibility Criteria


  • Histologically documented invasive adenocarcinoma of the prostate staged pT3 pN0 after radical prostatectomy
  • Preoperative staging must have been T0-3 N0 M0 based on physical exam, chest x-ray, bone scan, CT or MRI of entire pelvis and abdomen, and serum PSA
  • At least 1 of the following features must be present:
  • Complete capsule invasion (i.e., perforation)
  • Positive surgical margins (microscopic or gross)
  • Seminal vesicle invasion
  • Radiotherapy must begin within 16 weeks following surgery, after recovery of urinary function



  • 75 and under

Performance status:

  • WHO 0-2


  • Not specified


  • Not specified


  • Not specified


  • No other malignancies


Biologic therapy:

  • Not specified


  • Not specified

Endocrine therapy:

  • No more than 4 months of preoperative hormonal therapy


  • Not specified


  • Radical prostatectomy required within 12 weeks with recovery of urinary function

Trial Contact Information

Trial Lead Organizations/Sponsors

European Organization for Research and Treatment of Cancer

    Michel Bolla, Study Chair
    Hein van Poppel, Study Chair

    Link to the current ClinicalTrials.gov record.
    NLM Identifier NCT00002511
    ClinicalTrials.gov processed this data on January 22, 2015

    Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.